Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 210

Results For "disease"

2098 News Found

Lupin launches penicillamine tablets USP
News | March 04, 2021

Lupin launches penicillamine tablets USP

Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).


Pharma stalwarts demystify COVID-19 impact on industry
News | March 01, 2021

Pharma stalwarts demystify COVID-19 impact on industry

Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.


Zydus Cadila receives final approval from USFDA for Droxidopa capsules
News | February 20, 2021

Zydus Cadila receives final approval from USFDA for Droxidopa capsules

It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.


Lupin receives approval for Droxidopa capsules
News | February 20, 2021

Lupin receives approval for Droxidopa capsules

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness


Lupin launches posaconazole delayed-release tablets
News | February 18, 2021

Lupin launches posaconazole delayed-release tablets

posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.


Zydus completes enrolment for two Phase Ill trials of Desidustat
News | February 08, 2021

Zydus completes enrolment for two Phase Ill trials of Desidustat

The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.


Zydus eyes $6 bn market with strong COVID-19 portfolio
News | January 18, 2021

Zydus eyes $6 bn market with strong COVID-19 portfolio

With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential


Bayer gearing up for 2021-2030 decade
News | January 16, 2021

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business